NEW YORK (AP) — Recent federal court decisions concerning access to abortion medication are pushing a divisive political topic back into the national conversation as midterm elections approach, with control of Congress hanging in the balance during President Donald Trump’s current term.
A federal appeals court decision on Friday limited mail-order access to mifepristone prescriptions, affecting one of the nation’s most widely used abortion procedures. This represents the most significant change to federal abortion policy since the Supreme Court’s 2022 ruling that permitted states to implement abortion prohibitions.
The Supreme Court subsequently issued a temporary order on Monday restoring widespread access to the medication while continuing to review the matter, potentially leading to a ruling with far-reaching implications for both patients and healthcare providers.
While it remains uncertain whether these recent court decisions will influence this year’s electoral outcomes, particularly when economic concerns are anticipated to dominate voter priorities, advocacy organizations on both sides are optimistic about mobilizing their supporters.
Abortion rights organizations are already developing strategies to connect with voters who may be more inclined to support Democratic candidates due to concerns about additional restrictions. Conversely, anti-abortion activists who believe the GOP-controlled federal government has been insufficient in banning these medications are cautioning that traditionally reliable Republican voters might abstain from future elections, with one prominent anti-abortion leader describing the situation as “a five-alarm crisis” for the GOP.
Following the reversal of Roe v. Wade in 2022, multiple states voted to incorporate abortion protections into their state constitutions, generating unprecedented voter participation that sometimes helped Democratic candidates win other races on the same ballot.
However, Democratic pollster Celinda Lake believes the issue had begun losing some of its impact among voters, not due to lack of concern among Democrats, but because they feel that the “damage has been done.”
Although Friday’s court decision has been temporarily suspended, it served as a reminder to voters that their access to abortion medication through telehealth services isn’t secure, even in states with protected abortion rights, Lake explained. This situation created a significant but “horrific” chance to inform voters about what could be at risk in this year’s midterms, she noted.
Mini Timmaraju, president and CEO of the abortion rights group Reproductive Freedom for All, indicated that voter outreach regarding the uncertain nature of abortion access will be incorporated into her organization’s midterm strategy. This includes reaching out to voters who backed Trump while also supporting abortion rights in their state elections in 2024.
“The only way for us to really stop this back and forth is to have abortion access be legal in all 50 states,” she stated. “The only way we do that is through federal legislation, which makes the midterm elections even more urgent.”
Meanwhile, the Republican coalition is dealing with an increasingly frustrated conservative wing of abortion opponents who anticipated Trump would deliver on his commitment to be the “most pro-life president in history” but claim they haven’t witnessed it thus far.
The most pressing concern involves a Food and Drug Administration safety assessment of mifepristone that anti-abortion organizations hope will lead to additional restrictions, including preventing its prescription through telehealth services. Anti-abortion groups have pressed FDA commissioner Dr. Marty Makary to expedite the review, while the administration maintains it “is taking care to do this study properly and in the right way.”
On Monday, the anti-abortion organization SBA Pro-Life America escalated its messaging, demanding Makary’s dismissal over the matter.
“This is a five-alarm crisis for the pro-life movement and for the GOP,” the group’s president Marjorie Dannenfelser said in a statement. “The GOP cannot win without its base and simply will not get the enthusiasm that drives turnout without leadership from the top.”
Trump, whose first-term judicial appointments helped create the Supreme Court majority that voted to overturn Roe, has implemented some measures that abortion opponents have applauded, including efforts to deny funding to Planned Parenthood and initiating investigations into states that mandate state-regulated health insurance plans to cover abortion procedures.
However, he has frequently attempted to avoid the abortion topic, stating he believes it should be decided by individual states. The president supported abortion rights publicly until entering politics in 2015, and his wife, Melania Trump, declared her broad support for abortion rights in 2024.
Anti-abortion activists indicate they have no intention of allowing Trump to sidestep the issue for the rest of his presidency. Marc Wheat, general counsel at former Vice President Mike Pence’s political advocacy organization Advancing American Freedom, said his group will intensify pressure on the administration. This will include urging the FDA to quickly release mifepristone documents it owes the group through legal action.
“President Trump thinks that pro-life is a loser,” Wheat stated. “He might see that the pro-lifers may not turn out in the numbers that he needs.”
Despite mounting pressure from conservative groups for Trump and the Republican-controlled Congress to limit medication abortion access, Republicans nationwide are far from unified in supporting that stance.
Approximately two-thirds of Americans opposed nationwide prohibitions on mifepristone, according to a KFF poll conducted in late 2024. Most Democrats and independents rejected such bans, while Republicans showed more division on the issue.
American perspectives on abortion remain nuanced, with roughly two-thirds of U.S. adults believing abortion should be legal in most or all circumstances, according to AP-NORC polling data. Relatively few Americans think abortion should be prohibited in all situations.
At least one abortion opponent, Americans United for Life CEO John Mize, said he is concentrating on gradual progress rather than the comprehensive changes some of his colleagues are demanding. While he wishes the FDA would accelerate its safety review, he acknowledges that not all Americans share his position.
“I think there is advancement being made in a positive direction,” he said. “While it might not meet the pace that many in the pro-life movement want to see, I think it meets the acceptable place of where we’re at culturally.”
